Tevogen Bio Holdings Inc. (TVGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $406.59M
Last updated: Nov 17, 2026 at 3:04 AM ET
Tevogen Bio Holdings Inc. (TVGN) Financials: Revenue, Profit and Cash Flow
Tevogen Bio Holdings reported revenue of $0 for the fiscal year ended Jun 30, 2026. That year, net income was -$26.28M, operating cash flow was -$12.33M and free cash flow was -$12.39M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$5.76M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Jun 2026, with an operating loss of $26.14M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $0 | N/A | N/A | N/A | N/A |
| Jun 2025 | $0 | N/A | N/A | N/A | N/A |
| Jun 2024 | $0 | N/A | N/A | N/A | N/A |
| Jun 2023 | $0 | N/A | N/A | N/A | N/A |
| Jun 2022 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Cost of revenue | N/A | $403.58K | $378.36K | N/A | N/A |
| Gross profit | N/A | -$403.58K | -$378.36K | N/A | N/A |
| Research and development | $11.11M | $31.03M | $4.40M | $5.77M | $2.96M |
| Operating income | -$26.14M | -$53.56M | -$8.84M | -$953.08K | -$4.62M |
| Net income | -$26.28M | -$10.11M | -$60.48M | $4.41M | -$15.60M |
| EBITDA | -$25.57M | -$13.14M | N/A | $4.64M | N/A |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $396.59K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | -$60.14K | -$59.05K | -$85.79K | -$27.23K | -$290.78K | -$103.55K | N/A | -$101.74K | -$99.99K | -$98.30K | -$100.87K | -$93.58K |
| Operating income | -$5.66M | -$5.40M | -$4.61M | -$5.73M | -$5.44M | -$10.36M | -$9.42M | -$6.09M | -$8.60M | -$29.52M | -$2.01M | -$2.33M |
| Net income | -$5.76M | -$5.45M | -$4.68M | -$5.73M | -$5.50M | -$10.37M | -$9.44M | -$5.91M | -$6.05M | $11.26M | -$3.63M | -$3.90M |
Balance Sheet
As of Jun 2026, total debt of $6.38M exceeded cash and equivalents by $5.83M. Shareholder equity was negative, at -$8.23M, as total liabilities of $12.62M exceeded total assets of $4.38M.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Total assets | $4.38M | $3.46M | $5.51M | $7.74M | $7.66M |
| Current assets | $1.54M | $2.36M | $1.72M | $5.84M | $7.17M |
| Cash and equivalents | $552.37K | $1.28M | $1.05M | $5.48M | $7.12M |
| Total liabilities | $12.62M | $10.14M | $99.93M | $41.69M | $24.15M |
| Short-term debt | $1.98M | $1.88M | $80.96M | $278.21K | N/A |
| Long-term debt | $4.40M | $1.00M | $14.22M | $39.30M | $23.48M |
| Shareholder equity | -$8.23M | -$6.67M | -$94.43M | -$33.95M | -$16.49M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.73M | $4.92M | $4.38M | $4.49M | $4.27M | $4.07M | $3.46M | $4.29M | $3.31M | $3.36M | $5.51M | $6.36M |
| Total liabilities | $13.62M | $14.76M | $12.62M | $12.32M | $13.75M | $11.79M | $10.14M | $10.48M | $10.94M | $9.17M | $99.93M | $97.16M |
| Cash and equivalents | $1.08M | $692.30K | $552.37K | $1.04M | $685.23K | $1.97M | $1.28M | $2.33M | $1.14M | $1.32M | $1.05M | $2.61M |
| Shareholder equity | -$8.89M | -$9.84M | -$8.23M | -$7.82M | -$9.48M | -$7.72M | -$6.67M | -$6.19M | -$7.63M | -$5.80M | -$94.43M | -$90.80M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Jun 2026.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.33M | -$12.00M | -$8.17M | -$8.66M | -$5.27M |
| Capital expenditures | $64.44K | $0 | $133.00K | $479.04K | $109.73K |
| Free cash flow | -$12.39M | -$12.00M | -$8.30M | -$9.13M | -$5.38M |
| Investing cash flow | -$64.44K | N/A | -$133.00K | -$479.04K | -$109.73K |
| Financing cash flow | $11.66M | $12.23M | $3.87M | $7.50M | $12.50M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.01M | -$2.73M | -$2.18M | -$3.65M | -$3.19M | -$3.31M | -$3.05M | -$3.80M | -$2.98M | -$2.16M | -$1.98M | -$1.80M |
| Capital expenditures | $3 | $1 | $64.43K | $4 | $3 | $3 | $0 | $1 | $0 | $5 | $2 | $2 |
| Free cash flow | -$3.01M | -$2.73M | -$2.25M | -$3.65M | -$3.19M | -$3.31M | -$3.05M | -$3.80M | -$2.98M | -$2.16M | -$1.98M | -$1.80M |
Frequently Asked Questions About TVGN
What is Tevogen Bio Holdings' annual revenue?
Tevogen Bio Holdings reported revenue of $0 for the fiscal year ended Jun 30, 2026.
Is Tevogen Bio Holdings profitable?
No. Tevogen Bio Holdings reported net income of -$26.28M for the fiscal year ended Jun 30, 2026.
How much free cash flow does TVGN generate?
For the fiscal year ended Jun 30, 2026, operating cash flow of -$12.33M minus capital expenditures of $64.44K produced free cash flow of -$12.39M.
How much debt does Tevogen Bio Holdings have?
The balance sheet dated Jun 30, 2026 reported long-term debt of $4.40M, short-term debt of $1.98M and cash and equivalents of $552.37K.
TVGN pages: Overview, Forecast, Financials, Competitors